Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-090-3 | CAS number: 51-34-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
The most sensitive chronic NOAEL value of 5 mg/kg bw (five days a week) was determined in a NTP (National Toxicology Program) study conducted with rats for 2 years (oral gavage) with Scopolamine hydrobromide trihydrate. The exposure for five days per week under test conditions was extrapolated to seven days per week resulting in the NOAEL value of 3.57 mg/kg bw/day. As the study was conducted with the read across substance Scopolamine hydrobromide trihydrate a molecular weight conversion was done. After molecular weight conversion a NOAEL value of 2.46 mg/kg bw/day could be used for DENEL calculation.
No evidence of carcinogenic activity for the substance was found in the study, the NOAEL value is based on survival.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 453 (Combined Chronic Toxicity / Carcinogenicity Studies)
- Deviations:
- not specified
- GLP compliance:
- yes
- Remarks:
- Food and Drug Administration (FDA) Good Laboratory Practice Regulations (21 CFR, Part 58)
- Species:
- rat
- Strain:
- other: F-344/N
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Simonsen Laboratories (Gilroy, CA)
- Age at study initiation: approximately 6 weeks
- Housing: five per cage; Cages: Polycarbonate (Lab Products Inc., Maywood, NJ), changed twice weekly; Bedding: Sani-Chip® hardwood chips (P.J. Murphy Forest Products Corp., Montville, NJ); Cage filters: DuPont 2024 spun-bonded polyester (Snow Filtration Co., Cincinnati, OH); Racks: Stainless steel (Lab Products Inc., Maywood, NJ), rotated once every 2 weeks
- Diet (e.g. ad libitum): NIH-07 open formula pellet diet (Zeigler Brothers, Inc., Gardners, PA) available ad libitum
- Water (e.g. ad libitum): tap water (Columbus Municipal Supply) via automatic watering system (Edstrom Industries, Waterford, WI) available ad libitum
- Acclimation period: 14 days quarantinedENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.7 to 23.3- Humidity (%): 24 to 72
- Air changes (per hr): minimum of 10 changes/hour
- Photoperiod (hrs dark / hrs light): 12 hours/day fluorescent light - Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- deionized
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Stability studies of the 11 and 0.2 mg/mL dose formulations were conducted by the analytical chemistry laboratory. For the 11 mg/mL formulation, samples were prepared by dissolving scopolamine hydrobromide trihydrate in deionized water and diluting to volume. Aliquots (5 mL) were mixed with internal standard solution (0.4 mg/mL acetophenone in acetonitrile) and were further diluted with 0.007 M aqueous sodium heptanesulfonic acid. The samples were then analyzed by HPLC using a Waters C18 Nova Pak column, with a mobile phase of water:acetonitrile (70:30), at a flow rate of 1.0 mL/minute, and with ultraviolet detection at 229 nm. For the 0.2 mg/mL formulation, samples were prepared by dissolving scopolamine hydrobromide trihydrate in deionized water and diluting to volume. Aliquots (7 mL) were mixed with internal standard solution (0.04 mg/mL propiophenone in acetonitrile) and were analyzed by HPLC with the same system used to analyze the 11 mg/mL formulation but with a mobile phase ratio of 75:25. The stability of the dose formulations was confirmed for at least 3 weeks at room temperature when stored in the dark or for at least 3 hours at room temperature and open to air and light.Periodic analyses of the dose formulations of scopolamine hydrobromide trihydrate were conducted at the study laboratory using HPLC for the 2-year studies. During 2-year studies, dose formulations were analyzed every 6 to 8 weeks. During the 2-year studies, 92% (72/78) of the dose formulations were within 10% of the target concentration with no value differing more than 20% from the target concentration. For the 2-year studies, results of periodic referee analyses performed by the analytical chemistry laboratory indicated good agreement with the results of the study laboratory.
- Duration of treatment / exposure:
- 104 weeks
- Frequency of treatment:
- once daily, 5 days per week
- Remarks:
- Doses / Concentrations: 0, 1, 5, 25 mg/kg body weight Basis: actual ingested
- No. of animals per sex per dose:
- 60
- Control animals:
- yes
- yes, historical
- Details on study design:
- - Dose selection rationale: Based on the lower mean body weights in all dosed animals and lower survival in 400 mg/kg males and 1200 mg/kg males and females compared to body weights and survival in the control groups in the 14 weeks in rat study, doses selected for the 2 years study were 1, 5, and 25 mg/kg.
- Observations and examinations performed and frequency:
- ANIMAL OBSERVATIONS: Yes - Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes - Time schedule: every 3-4 weeks during the first 13 weeks and monthly thereafter
BODY WEIGHT: Yes - Time schedule for examinations: weekly through the first 13 weeks, monthly thereafter, and at the end of the study
OPHTHALMOSCOPIC EXAMINATION: Yes- Time schedule for examinations: Before the study began and at 15 months- Dose groups that were examined: 10 male and 10 female per group
HAEMATOLOGY: Yes - Time schedule for collection of blood: At the 15-month interim evaluation (within the hour after dosing)
- Anaesthetic used for blood collection: Yes (CO2:O2))
- How many animals: 10 male and 10 female rats per group (excluding female rats that received 1 mg/kg*)
- Parameters which were examined: hematocrit; hemoglobin; erythrocyte, reticulocyte, and nucleated erythrocyte counts; mean cell volume; mean cell hemoglobin; mean cell hemoglobin concentration; platelet count; and leukocyte count and differentials.* Because of a flooding incident that killed 16 female rats receiving 1 mg/kg, no females in this dose group were bled or necropsied at 15 months.
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes- Time schedule for examinations: Prior to the study, on the first day of study, and after 3, 6, 9, 12, and 24 months of exposure.
- Dose groups that were examined: Ten male and ten female rats per dose group. The same animals were used at each time point.
- Battery of functions tested: motor activity, grip strength, thermal sensitivity, startle responsiveness, and passive avoidance.
NECROPSY: Yes- All core-study animals were necropsied. Organs weighed at the 15-month interim evaluations were the right epididymis, right kidney, liver, right testis (excluding female rats receiving 1 mg/kg). At necropsy, all organs and tissues were examined for gross visible lesions.
PLASMA SCOPOLAMINE DETERMINATION: Yes- At 15 months, 10 male and 10 female rats were bled for plasma scopolamine determination. (Rats had been bled one hour earlier for hematology evaluations.) - Sacrifice and pathology:
- HISTOPATHOLOGY/GROSS PATHOLOGY: Yes; Complete histopathologic examinations were performed on all core-study animals. In addition to gross lesions, tissue masses, and associated lymph nodes, the tissues examined included: adrenal gland, bone and marrow, brain, clitoral gland, esophagus, heart, kidney, large intestine (cecum, colon, and rectum), small intestine (duodenum, jejunum, and ileum), liver, lung, lymph nodes (mandibular or mesenteric), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, stomach (forestomach and glandular stomach), testis with epididymis and seminal vesicle, thymus, thyroid gland, trachea, urinary bladder, and uterus.
- Statistics:
- The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958).Statistical analyses for possible dose-related effects on survival used Cox's (1972) method for testing two groups for equality and Tarone's (1975) life table test to identify dose-related trends. All reported P values for the survival analyses are two sided.For calculation of statistical significance, the incidences of most neoplasms and all non-neoplastic lesions are given as the ratio of the number of affected animals to the number of animals with the site examined microscopically.Tests: prevalence analysis of Dinse and Lagakos (1983), further described and illustrated by Dinse and Haseman (1986).Other methods: the life table test (Cox, 1972; Tarone, 1975), appropriate for rapidly lethal neoplasms, the Fisher exact test and the Cochran-Armitage trend test (Armitage, 1971; Gart et al., 1979)Organ and body weight data (approximately normal distribution) were analyzed using the parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972).Hematology and epididymal spermatozoal data (typically skewed distribution), were analyzed using the nonparametric multiple comparison methods of Shirley (1977) and Dunn (1964).Jonckheere’s test (Jonckheere, 1954) was used to assess the significance of the dose-related trends and to determine whether a trend-sensitive test (Williams’ or Shirley’s test) was more appropriate for pairwise comparisons than a test that does not assume a monotonic dose-related trend (Dunnett’s or Dunn’s test). Prior to analysis, extreme values identified by the outlier test of Dixon and Massey (1951) were eliminated.Average severity values were analyzed for significance using the Mann-Whitney U test (Hollander and Wolfe, 1973).Because vaginal cytology data are proportions, an arcsine transformation was used. Treatment effects were investigated by applying a multivariate analysis of variance (Morrison, 1976).
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Clinical findings included bilateral pupillary dilation in all dosed males and females. Ophthalmic examination revealed no significant findings.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- The survival of female rats receiving 1 and 25 mg/kg were significantly lower than that of the control group. The lower survival in 1 mg/kg females was due primarily to a cage flooding accident resulting from a malfunctioning automatic watering system valve
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Mean body weights of 1 and 5 mg/kg males and females were similar to those of the controls throughout the study. The mean body weight of 25 mg/kg males was slightly lower than that of the control group from about week 25 through week 97. The mean body weight of 25 mg/kg females was lower than that of the control group from week 25, and the final mean body weight was 81% that of the controls.
No adverse effects observed. - Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No adverse effects.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Compared to controls, hematocrit was slightly higher in the 25 mg/kg male rats, similar to the effects observed in the 14-week study; this would be consistent with dehydration resulting in hemoconcentration. The reticulocyte count in 25 mg/kg female rats was slightly lower than that in the control group. This result is consistent with the lower body weights, and thus a decreased nutritional status, exhibited by these animals.
No adverse effects. - Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No adverse effects.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No adverse effects (See Table 2)
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- The incidences of adenoma of the pituitary gland pars distalis decreased with increasing dose in both male and female rats; however, this trend was only significant in males (males: vehicle control, 19/49; 1 mg/kg, 17/49; 5 mg/kg, 13/50; 25 mg/kg, 10/50; females: 20/50, 13/60, 14/50, 10/50). The incidences of adenoma of the pituitary gland pars distalis in 25 mg/kg males and all groups dosed females were below the NTP historical control range. The incidences of hyperplasia were not significantly different from those in the control groups.The incidences of mononuclear cell leukemia in 25 mg/kg males and females were significantly lower than those of the control groups (males: 33/50, 21/50, 26/50; females: 20/50, 6/60, 13/50, 4/50). The incidence of mononuclear cell leukemia in females receiving 25 mg/kg was well below the NTP historical range
No adverse effects observed. - Neuropathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Horizontal motor activity of 25 mg/kg females was significantly greater than that of the control group on days 90, 180, and 360. The startle response of 5 and 25 mg/kg females was significantly lower than that of the control group on day 90. On day 180, passive avoidance by 25 mg/kg males was significantly lower than that by the control group.
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No adverse effects.
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- No adverse effects.
- Description (incidence and severity):
- Plasma Scopolamine Determinations:Serum samples collected from rats 1 hour after dosing were analyzed to determine serum scopolamine concentrations. Serum scopolamine concentration analyses indicated 6 ng scopolamine/mL serum for the 5 mg/kg female sample and 12 and 28 ng/mL for the 25 mg/kg male and female samples, respectively. The amounts of scopolamine in the other serum samples were below the minimum detection limit (4 ng/mL) of the analysis method.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 5 other: mg/kg bw
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- mortality
- Remarks on result:
- other: dosage 5 days a week converted in 3.57 mg/kg bw/day
- Dose descriptor:
- NOAEL
- Effect level:
- >= 25 other: mg/kg bw
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- mortality
- Remarks on result:
- other: dosage 5 days a week
- Critical effects observed:
- not specified
- Conclusions:
- Under the test conditions a NOAEL of >=25 mg/kg bw (male) and a NOAEL of 5 mg/kg bw (female) was determined. The exposure for five days per week under test conditions was extrapolated to seven days per week resulting in the NOAEL value of 3.57 mg/kg bw/day for female.
Reference
Table 1: Summary of the 2 -Year Carcinogenesis Toxicology Study of Scopolamine Hydrobromide Trihydrate
Male F344/N Rats | Female F344/N Rats | |
Doses | 0, 1, 5, 25 mg/kg in water by gavage | 0, 1, 5, 25 mg/kg in water by gavage |
Body weights | 25 mg/kg group lower than control group | 25 mg/kg group lower than control group |
2 -Year survival rates | 20/50, 14/50, 22/50, 28/50 | 34/50, 17*/60, 26/50, 22/50 |
Nonneoplastic effects | None | None |
Neoplastic effects | None | None |
Levels of evidence of carcinogenic activity | No evidence | No evidence |
*The lower survival in 1 mg/kg females was due primarily to a cage flooding accident resulting froma malfunctioning automatic watering system valve.
Table 2: Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats at the 15-Month Interim Evaluation in the 2-Year Gavage Study of Scopolamine Hydrobromide Trihydrate
Vehicle Control | 1 mg/kg | 5 mg/kg | 25 mg/kg | |
Male | ||||
n | 10 | 10 | 10 | 10 |
Necropsy body wt | 493 +- 9 | 492 +- 11 | 481 +- 10 | 448 +- 9** |
R. Epididymis | ||||
Absolute | 0.423 +- 0.022 | 0.464 +- 0.012 | 0.428 +- 0.014 | 0.441 +- 0.017 |
Relative | 0.86 +- 0.04 | 0.94 +- 0.02 | 0.89 +- 0.03 | 0.99 +- 0.04* |
R. Kidney | ||||
Absolute | 1.614 +- 0.029 | 1.565 +- 0.050 | 1.543 +- 0.047 | 1.366 +- 0.036** |
Relative | 3.28 +- 0.07 | 3.18 +- 0.06 | 3.20 +- 0.06 | 3.06 +- 0.08 |
Liver | ||||
Absolute | 18.032 +- 0.477 | 17.953 +- 0.579 | 17.382 +- 0.580 | 15.319 +- 0.481** |
Relative | 36.65 +- 0.83 | 36.46 +- 0.71 | 36.11 +- 0.81 | 34.21 +- 0.84 |
R. Testis | ||||
Absolute | 1.884 +- 0.229 | 1.680 +- 0.075 | 1.777 +- 0.169 | 1.669 +- 0.142 |
Relative | 3.83 +- 0.47 | 3.43 +- 0.18 | 3.67 +- 0.30 | 3.76 +- 0.37 |
Female | ||||
n | 10 | 10 | 10 | |
Necropsy body wt | 293 +- 12 | -b) | 285 +- 5 | 274 +- 7 |
R. Kidney | ||||
Absolute | 0.938 +- 0.017 | - | 0.869 +- 0.014** | 0.845 +- 0.021** |
Relative | 3.23 +- 0.10 | - | 3.06 +- 0.07 | 3.09 +- 0.04 |
Liver | ||||
Absolute | 9.198 +- 0.322 | - | 8.869 +- 0.147 | 8.392 +- 0.235* |
Relative | 31.54 +- 0.92 | - | 31.19 +- 0.43 | 30.70 +- 0.59 |
* Significantly +- (P<=0.05) from the control group by Williams' or Dunnett's test** P<=0.01a) Organ weights and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean +- standard error).b) Female rats in the 1 mg/kg group wen not necropsied at the interim evaluation due to high mortality. |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 2.46 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the available data, the substance will not be classified.
Additional information
A 2 -year carcinogenicity study (NTP) was conducted in accordance with good scientific principles with the read across substance Scopolamine hydrobromide trihydrate. Under the test conditions a NOAEL of >= 25 mg/kg bw (male) and a NOAEL of 5 mg/kg bw (female) was determined for rats (F344/N) and a NOAEL of >= 25 mg/kg bw (female/male) was determined for mice (B6C3F1).The exposure for five days per week under test conditions was extrapolated to seven days per week resulting in the NOAEL value of 3.57 mg/kg bw/day. As the study was conducted with the read across substance Scopolamine Hydrobromide Trihydratea molecular weight conversion was done. After molecular weight conversion the NOAEL value 2.46 mg/kg bw/day could be used for DENEL calculation.
Under the condition of these 2 -year gavage studies, there was no evidence of carcinogenic activity of the read across substance scopolamine hydrobromide trihydrate in male or female rats or mice administered 1, 5, or 25 mg/kg. All NOAEL values are based on survival.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.